Daniel Lock, Specialist - Pharmaceutical Development shares his insights on the evolution of nebulisers, and how advancements in technology can improve patient care and inhaled product development. In this episode, Dan discusses how smart nebulisers can improve lung deposition for inhaled therapies, provide valuable patient data in clinical trials, and expand the profile of patients who may benefit from nebulised treatment.

Hear from Vectura’s CEO Will Downie as shares his thoughts on our performance in 2020 and the progress we’ve made transforming to become a market leading inhalation CDMO.

What are the unique challenges involved in developing inhaled generic medicines? Following the US FDA’s approval of VR315 (US), hear from Martin Oliver, our SVP Delivery Management – DPI and pMDI Platforms, as he explains in this podcast.

In our latest episode, hear Sharon Johnson, our EVP Delivery Management, talk about the importance of science at Vectura, our inhalation CDMO transformation, managing the challenges of COVID-19 and leadership.

In the latest podcast in our series, Will Downie Vectura’s CEO talks about coping with the COVID crisis, our CDMO transformation and delivering for customers and patients.

Andreas Meliniotis, Director of Device Development, shares his insights on new trends in device development and how simplicity, usability and connectivity ultimately helps patients. Andreas will also help navigate the complex area of DPI combination product development in a free webcast on 24th June. Register here: https://bit.ly/30qtaz4

How do you identify the best opportunities to repurpose or reposition existing drugs for inhaled administration? Geraldine Venthoye, EVP Product Development, shares her insights and talks about Vectura’s capabilities in the inhalation space. You can also read more in the latest edition of Medicine Maker here.

Sandy Munro, VP of Pharmaceutical Development, talks about Vectura’s involvement in the all-digital Respiratory Drug Delivery Congress 2020, the science we’ll be presenting, and how we’re helping customers develop inhaled medicines.